1. Rational Pharmacotherapy Selection for Insomnia

3. Insomnia Prevalence

4. Triad of Insomnia Symptoms

5. Insomnia Subtypes

6. Insomnia-Associated Conditions and Outcomes

7. Falls in Older Adults

8. Bidirectional Relationship Between Sleep and Health

9. CSF-Orexin Concentrations in Patients With and Without MCI and Sleep Complaints

10. The Rational Treatment of Insomnia Is Based on the Neurobiology of Sleep

11. Arousal Systems in People With Insomnia That Do not Deactivate From Waking to Sleep

12. Wake-Promoting vs Sleep-Inducing Brain Centers and Neurotransmitters

13. Hyperarousal Model of Insomnia

14. Arousal Systems in People With Insomnia That Do not Deactivate From Waking to Sleep

15. Goals of Treatment in Insomnia

16. Personalized Treatment Selection

17. CBT-I First-Line Therapy

18. Site of Action of Drugs to Treat Insomnia

19. Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

20. FDA-Approved Insomnia Medications

21. Half-Life of FDA-Approved Drugs for the Treatment of Insomnia

22. Drugs in the Pipeline for Insomnia

23. AASM Chronic Insomnia Clinical Guideline Consensus Recommendations

24. Conclusions

25. Abbreviations

26. Abbreviations (cont)

27. Abbreviations (cont)